Linical Accelovance is Now Linical Americas
STUART, FL. May 19, 2020 -
Linical, a full service, midsized, global Contract Research Organization (CRO) has streamlined its regional naming structure as a next step in the organization’s evolution. The company’s North American entity, previously known as Linical Accelovance America, will now be doing business as Linical Americas. Linical USA, Inc. will remain the parent company of Linical Americas. The name shift better aligns the organization’s North American operations under the unified Linical umbrella, as well as signals the company’s plans for further expansion within North and South America.
“We are pleased to take this final step to become fully integrated within the Linical organization,” remarked Vita Lanoce, CEO of Linical Americas. “As always, we are committed to offering clients the same professional and personalized approach to clinical research they have come to expect of us. We look forward to bringing this same level of customer service as we continue to expand our footprint throughout the Americas. The entire Linical organization across the Americas, Europe, and Asia is proud to be the CRO of choice for many pharmaceutical and biotechnology companies around the world.”
For more information, please visit the Linical Americas website at https://www.linicalamericas.com and follow Linical Americas on social media.
Linical is a public, midsized CRO headquartered in Japan with a significant presence across North America, Europe, and Asia-Pacific. Linical provides the full spectrum of drug development services from early stage to large-scale, multinational studies. The company’s areas of expertise include Phase I-IV oncology, vaccine, infectious disease, CNS and general medicine.